Varian linacs localized in Dubna received the status of domestic ones

Fabrika RTT LLC (Fabrika RTT, part of R-Pharm Group of Alexey Repik) has received the CT-1 certificate confirming the fulfillment of localization norms for the line of Varian Halcyon system for radiotherapy, assembled in Special Economic Zone (SEZ) Dubna. Now the medical equipment will be able to use the preferences on the market of the state order as Russian products.

Certificate of origin CT-1 for Halcyon radiotherapy system unit for standard modification and Elite model was issued by the Chamber of Commerce and Industry of Moscow region on April 20, 2022.

According to Andrey Popov, CEO of Fabrika RTT, obtaining of CT-1 certificate will allow to reduce cost of the product as compared to imported analogues. The Halcyon linac is one of the latest devices presented by the major: Varian introduced the model in 2017, and in 2021 the production of the entire product line at the Dubna plant was mastered, notes the CEO of Fabrika RTT.

The key advantages of the linac are its throughput capacity of over one hundred patients per day, minimal requirements for strengthening the radiation protection of the room, which allow installing the device in a canyon designed for gamma therapy devices. The apparatus allows radiation therapy for patients with neoplasms of the head and neck, chest, abdomen, pelvis, central and peripheral nervous system, malignant diseases of the lymphoid system both for radical treatment and for palliative care.

The project of localization of Varian linac - Fabrika RTT in SEZ Dubna - in 2016 was initiated by co-founder of "PET Technology" Alexey Tsarkov. It was assumed that the organization of production would require 900 million rubles in investments, and the plant would be launched in 2018. Tsarkov later withdrew from the project, and his share through R-Pharm Ventures LLC was bought by Alexey Repik.

In the spring of 2019, Fabrika RTT verified certificates for Clinac and Unique with Roszdravnadzor and began assembling linacs. The production capacity of the facility is up to 75 linacs per year. The first deliveries of localized linacs started in February 2020 - Varian Unique system of Russian assembly was shipped to Yaroslavl Regional Clinical Oncology Hospital.

Plans to localize Halcyon became known in the summer of 2019. "Varian has the newest product, which is an order of magnitude different from all the products on the market - Halcyon. It's the most advanced, fastest and easiest to use in the company's lineup. After all, it's important that the equipment is easy to work on, so you can increase throughput. Halcyon meets these needs, we hope that next year it will also be Russian and will start to be produced here," Alexey Repik told Vademecum in July 2019.

In September 2019, the company signed an agreement to localize a new version of Halcyon. The document assumed the assembly of 200 linacs within five years. In the fall of 2021, Fabrika RTT localized production and received a regulatory approval from Roszdravnadzor to assemble linacs at the Dubna Special Economic Zone.

Since the end of 2021, Fabrika RTT has supplied more than 10 Halcyon devices of Russian assembly under the state program Fighting Against Cancer of the national project Healthcare.

According to SPARK-Interfax, Fabrika RTT LLC is 95% owned by Alexey Repik's R-Pharm Ventures and another 5% is owned by Andrey Popov. In 2021, the company earned 2.977 billion rubles, with a net profit of 158 million rubles. In 2020 the company was on the 4th place in the TOP 100 suppliers of the state medical products market according to the Vademecum analytical center with the volume of deliveries of 4,33 billion rubles.

Read more about the state order market for linas and the prospects of supplies under the national project in Vademecum's research and an interview with Andrey Popov, CEO of Fabrika RTT.

The source: Vademecum